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Abstract
Background—Attendance at biannual medical encounters has been proposed as a minimum 
national standard for adequate engagement in HIV care. Using data from the HIV Outpatient 
Study, we analyzed how well dates of HIV-related laboratory testing correlated with attendance at 
biannual medical encounters.
Methods—HIV Outpatient Study is an open prospective cohort study of HIV-infected patients 
receiving outpatient care in the United States. The data set included dates for laboratory 
measurements and medical encounters. We included patients with at least 1 HIV laboratory test 
(CD4 cell count or plasma HIV RNA viral load) during 2010–2011. An HIV laboratory test was 
defined as associated with a medical encounter if it occurred within 3 weeks of the encounter. We 
assessed the predictive value of HIV laboratory tests as a proxy for adequate engagement in 
clinical care, defined as having had ≥2 HIV laboratory tests within 1 year and performed >90 days 
apart.
Results—A total of 10,321 HIV laboratory tests were recorded from 2909 patients. Adequate 
engagement in clinical care based on medical encounters was 88.2% and 77.3% when based on 
laboratory tests. Using HIV laboratory tests to assess engagement had a sensitivity of 85.7%, 
specificity of 86.0%, and positive and negative predictive values of 97.9% and 44.5%, 
respectively. Of the 22.7% classified as not engaged in care by the proxy measure, over half 
(55.5%) were actually engaged.
Conclusions—Using laboratory monitoring reliably classified persons as engaged in care. Of 
the 22.7% of patients classified as not engaged in care, most were actually engaged.
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INTRODUCTION
Engagement in ongoing HIV care is recognized as an important clinical performance 
indicator,1 and attendance at biannual medical encounters has been proposed as a minimum 
US standard for engagement in care.2-6 Measuring attendance poses a major challenge for 
both medical providers and public health authorities,1 HIV-related medical visit attendance 
is not nationally reportable,7 and methods for monitoring attendance at the clinic level are 
not standardized. Under current standards of care,8-10 a patient’s HIV RNA viral load (VL) 
and CD4 cell count (CD4) are typically measured coincident with clinical evaluation every 
3–6 months after establishing care. These laboratory data (ie, measured values and dates of 
testing) are now reportable as part of routine HIV surveillance activities to the CDC’s HIV/
AIDS Reporting System to track national trends. Various medical and public health entities 
have proposed using these laboratory reports as proxy indicators for assessing engagement 
in care.1 Using data from the HIV Outpatient Study (HOPS), we examined the relationship 
between patient encounters and VL and CD4 laboratory reports to assess the extent to which 
the latter can be used as a surrogate for actual engagement in care. Because HOPS is a 
multisite longitudinal cohort, which collects both encounter and laboratory information for 
its participants, this data set is particularly apt to answer the question regarding whether 
laboratory data can adequately be used to assess engagement in care.
METHODS
The HIV Outpatient Study
The HOPS is an open, prospective, observational cohort study of HIV-infected patients 
enrolled at 9 public universities and private HIV specialty clinics located in 6 US cities. 
Patients must be at least 18 years of age and receiving HIV care at one of the clinics to be 
enrolled. Research coordinators located in each clinic abstract sociodemographic 
characteristics, diagnoses, treatments, encounters, and laboratory values from patients’ 
medical charts and enter these data into an electronic database for central processing and 
analysis. Since its inception, the HOPS protocol has been reviewed and approved annually 
by the CDC or each local site’s institutional review board. The study protocol conforms to 
the guidelines of the US Department of Health and Human Services for the protection of 
human subjects in research; all participants have provided written informed consent.
Study Population and Inclusion Criteria
In our analyses, we included data from HOPS patients with at least 1 HIV laboratory test, 
either a CD4 or VL measurement, performed from January 2010 through December 2011. 
We did not require a minimum number of medical encounters. We classified the following 
as medical encounters: routine visits, initial visits, provider visits, consultations, pharmacist 
encounters, outpatient surgical procedures, and any other or unknown visit types. Long-term 
rehabilitation, home care visits, telephone calls, research study visits, hospital stays, post-
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hospital follow-up visits, emergency room visits, and visits that were scheduled but not 
attended by the patient (ie, no-shows) were not included. CD4 and VL tests were excluded if 
the laboratory reported the sample volume was inadequate for testing (comprising 0.6% of 
specimens reported in the database)—failed attempts to test are not nationally reportable, 
and this circumstance should have warranted a repeat specimen collection event and test. 
We also excluded data from 1 HOPS site that did not provide HIV primary care (ie, 
provided solely HIV specialty care).
Definitions of Variables
The index date (ie, initiation of observation) for all patients was the date on which a 
specimen was collected for the first VL or CD4 measurement during the study period. We 
defined “engaged in care by encounters” as having at least 2 medical encounters within 12 
months that were at least 90 days apart. We defined the proxy measure, “engaged in care by 
laboratory monitoring,” as having at least 2 HIV laboratory test results reported within 12 
months and at least 90 days apart. We classified an HIV laboratory testing event as linked 
with a medical encounter if the specimen was collected within 3 weeks before or after an 
HIV-related medical encounter. Suppression of VL was defined as <400 copies per 
milliliter.
Analysis Methods
We calculated the sensitivity, specificity, positive predictive value, and negative predictive 
value of being engaged by laboratory monitoring as a measure for being engaged in care by 
medical encounters as the gold standard. We compared the characteristics of patients for 
whom all laboratory testing events were linked with a medical encounter and patients for 
whom at least 1 laboratory testing event was not linked with a medical encounter through χ2 
test.
For patients whose engagement in care was misclassified, we examined their characteristics 
by using the proxy measure of engagement in care by laboratory monitoring as compared 
with medical encounters. Using χ2 tests and Fisher exact tests, as appropriate, we compared 
demographic characteristics of patients classified as false positive (ie, incorrectly classified 
as engaged) or false negative (ie, incorrectly classified as not engaged) with those of patients 
whose engagement was correctly classified through the proxy measure.
For laboratory testing events not linked with medical encounters, we used a generalized 
estimating equations model7 to explore associated patient characteristics present at the time 
the specimen was collected while controlling for correlations arising from multiple 
observations per patient. We used bivariate and multivariate logistic regression to assess 
characteristics associated with a laboratory testing event without an associated medical 
encounter. Missing values were multiply imputed for race/ethnicity, education, insurance, 
HIV transmission risk group, antiretroviral therapy (ART) exposure, VL suppression, 
previous VL suppression, and CD4.11 Multiple imputation fills in plausible responses for 
missing values based on existing values within the data, resulting in multiple imputed data 
sets; the outcomes resulting from analysis on these multiple data sets are then combined to 
estimate the outcome from the original data set. We included variables with univariate 
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associations at P value <0.05 in multivariable models.11 All analyses were performed using 
SAS version 9.2 (SAS Institute, Cary, NC). We used the HOPS data set available as of 
March 31, 2012, for this analysis.
RESULTS
Laboratory Testing Events and Medical Encounters
We included in our analysis 10,321 VL and CD4 laboratory testing events for 2909 unique 
HOPS patients seen during 2010–2011. During the same period, a total of 20,928 medical 
encounters were recorded. The median duration between patients’ first and last medical 
encounter was 14.5 months (interquartile range: 8.4–18.8, minimum: 0.0, maximum: 23.7). 
Of the 10,321 laboratory testing events, 519 were for CD4 measures alone, 1194 were for 
VL measures alone, and 8608 were events when both CD4 and VL were measured. The 
median time between a laboratory testing event and the nearest clinical visit was 0 days 
(interquartile range: 0–1.5); the median time varied by HOPS site from 0 to 6 days.
A total of 73.6% of laboratory testing events occurred on the same day as a medical 
encounter (see Figure S1, Supplemental Digital Content, http://links.lww.com/QAI/A585) 
and 89.3% of laboratory testing events occurred within the 3 weeks before or after a medical 
encounter. For 2148 (73.8%) patients, all laboratory testing events were classified as 
associated with a medical encounter (ie, occurred within 3 weeks before or after the medical 
encounter). The remaining 26.2% of patients with at least 1 HIV laboratory testing event 
performed outside the 3-week window (ie, classified as not associated with a medical 
encounter) were similar to patients who had each HIV laboratory testing event associated 
with a medical encounter in terms of age at index date, gender, education, disease stage, and 
HIV transmission risk group but were more likely to have been white non-Hispanic, to have 
been privately insured, to have been ART naive at index date, and to have been cared for at 
a private facility (Table 1).
Laboratory Testing Events as a Proxy for Engagement in Care
In our sample, 88.2% of patients met criteria for being engaged in care using medical 
encounter data. Engagement in care by encounters ranged from 76.2% to 97.8% across 
participating HOPS sites. Using the proxy measure of care by laboratory monitoring, 77.3% 
of patients were engaged in care, ranging from 47.9% to 96.1% across participating HOPS 
sites. Using the proxy of engagement in care by laboratory monitoring to measure 
engagement in care by encounters had a sensitivity of 85.7%, a specificity of 86.0%, and 
positive and negative predictive values of 97.9% and 44.5%, respectively (Table 2). Overall, 
14.2% of patients were misclassified. Three hundred sixty-six (12.6% overall, 88.4% of all 
misclassifications) patients were falsely classified as not engaged in care (falsely negative); 
that is, those patients were engaged in care by medical encounters but did not meet the 
definition of engagement in care by laboratory monitoring (see Figure S2, Supplemental 
Digital Content, http://links.lww.com/QAI/A585). Among the patients misclassified as not 
engaged in care by laboratory measures (22.7% overall), 55.5% (366/660) were actually 
engaged by encounters (Table 2). Only 48 (1.7%) patients were misclassified as falsely 
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engaged in care; that is, they appeared engaged in care by laboratory monitoring but were 
not actually engaged according to medical encounters.
Patients who were misclassified as not engaged through the proxy laboratory measure but 
who were actually engaged through medical encounters (false negatives) were more likely to 
be younger, female, Hispanic, or non-Hispanic black race/ethnicity and to belong to the 
high-risk heterosexual transmission risk group compared with those who were correctly 
classified (Table 3). In contrast, participants who were misclassified as engaged in care 
through the proxy laboratory measure but who were actually not engaged through 
encounters (false positives) were more likely to be of non-Hispanic black or non-Hispanic 
white race/ethnicity compared with those correctly classified, although there were small 
numbers of false positives (N = 48) from which to ascertain patterns.
Odds of an HIV Laboratory Testing Event Being Unassociated With a Medical Encounter
In bivariate analysis, younger age, non-Hispanic white race/ethnicity, receiving care in a 
private HOPS clinic, private insurance, and being ART naive at index date were associated 
with greater odds of having a laboratory test without a medical encounter (Table 4). When 
evaluated in a multivariate logistic generalized estimating equations model, receiving care in 
a private HOPS clinic and being ART naive at index date remained independently associated 
with having a laboratory testing event without an associated medical encounter (Table 4).
DISCUSSION
Using data from a multisite cohort study, we found that monitoring HIV laboratory testing 
events as a proxy for engagement in care reliably mirrored actual engagement as recorded 
by medical encounters. The proxy measure had a very high positive predictive value 
(97.9%) for actual engagement, and fewer than 15% of patients’ engagement statuses were 
misclassified. Most misclassifications were falsely negative (ie, laboratory testing events 
were absent when the patient was actually engaged in care by encounters) with only very 
few false positives (ie, a person not engaged in care by encounters appeared to be engaged 
by laboratory testing events). The low negative predictive value (44.5%) indicated that a 
substantial fraction of persons who did not seem to be engaged in care by laboratory 
measures (ie, falsely negative) were indeed engaged. Thus, the proxy measure functioned 
well at predicting engagement in care but was biased toward misclassifying a modest 
number of patients as not engaged in care rather than engaged; this circumstance resulted in 
a slight underestimation of care engagement based on laboratory measures.
Our estimate of engagement by laboratory monitoring exceeds the estimates of both Gardner 
et al and Hall et al (67% and 56%, respectively, among persons linked to care) but was 
similar to estimates reported by Sabharwal et al.12-14 Each of these estimates relied on 
laboratory data to infer attendance at clinical encounters among persons in care; Gardner et 
al synthesized published data, Hall et al analyzed data from 2 CDC national surveillance 
systems, the National HIV/AIDS Surveillance system and the Medical Monitoring Project, 
and Sabharwal et al analyzed New York City Registry data. Our higher estimate likely 
reflects the demography of our cohort, which in comparison with national data has a lower 
percentage of patients at risk of poor retention in care (ie, our population has a greater 
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proportion of participants who are of older age, male gender, and white non-Hispanic race/
ethnicity)13,15 and potentially reflects practice patterns and experience levels of HOPS 
physicians at our specialty clinics. Another explanation for why our estimate exceeds the 
estimates of engagement in care by laboratory monitoring published by others is that both 
laboratory and encounter information were gathered from the same source, reducing the 
probability of ascertainment bias and improving the linkage between laboratory tests and 
clinical visits when both actually occur. Similar to Sabharwal et al, when used to define 
establishment in care, laboratory data are likely to underestimate the true frequency.
Poor retention in care is associated with increased morbidity and mortality.1,16-18 
Monitoring engagement can help identify and prioritize patients at risk. Our findings suggest 
that surveillance and other administrative databases that capture CD4 and VL testing could 
be used effectively by public health departments to assist HIV care providers in their 
jurisdiction in identifying patients who may have disengaged from care. Public health 
departments could also ensure that patients who, from the provider’s perspective, seem to 
have disengaged are receiving at least a minimum standard of care by checking whether an 
HIV laboratory result has been reported from another source within their jurisdiction.
In practice, physicians do not necessarily order laboratory tests on the same day as a medical 
encounter. In some settings, depending on provider and patient preferences, patients may 
have blood drawn for laboratory tests before or after the medical encounter. We found in the 
HOPS that 89.3% of laboratory testing events occurred within the 3 weeks before or after a 
medical encounter. Increasing the window to 1 month did not appreciably improve the 
sensitivity and specificity of the performance measure (data not shown). However, we 
cannot determine whether this same window would be adequate for assessing 
correspondence of laboratory testing events and medical encounters in other models of care, 
such as health maintenance organizations, other unified health systems with multiple service 
points, or federally qualified health centers. We found that patients who were ART naive 
and received care in a private practice were more likely to have had a laboratory testing 
event not associated with a medical encounter. We have not conducted qualitative interviews 
with providers or patients to better understand this observation. We hypothesize that this 
demographic may comprise patients who had no overt illness requiring physician contact but 
required close laboratory monitoring to determine when ART should be started (ie, ART 
naive) or for whom there was a lower barrier, such as incentive from the provider’s 
perspective, to ensure patients attended a reimbursable medical encounter (ie, private 
practice).
Our analyses had a number of strengths and some limitations. HOPS is a robust prospective 
HIV cohort database composed of 20,928 encounters and 10,321 laboratory measurements 
recorded during 2010–2011 and representing care of 2909 patients. The HOPS database 
consists of a dynamic cohort of patients who have engaged in HIV care and consented to 
participate in a research study; thus, our findings cannot be necessarily extrapolated to other 
populations not engaged in specialty HIV care. Patients were categorized for analyses based 
on whether they had laboratory tests associated with medical encounters or not regardless of 
the number of laboratory tests or medical encounters recorded during the study period. Thus, 
different patients could have had varying numbers of medical encounters contributing to 
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their classification. It is possible that some patients had laboratory testing conducted outside 
the purview of the HOPS, so that they might have appeared to have no laboratory data when 
they were actually engaged. This would have led to an overestimation of false-negative 
classification, although it was small to begin with in this study.
In conclusion, monitoring dates of CD4 cell count and plasma HIV RNA VL testing events 
have been proposed as a means to measure engagement in clinical care in circumstances 
where attendance records are unavailable or difficult to analyze. We found that in a well-
characterized cohort study where both sets of information (ie, testing data and attendance 
records) were available from a data collection system designed to maximize completeness of 
their capture, HIV laboratory testing data reliably estimated attendance, and that such 
estimates were biased substantially more toward underestimation rather than overestimation. 
The generalizability of our findings may be limited. We recommend repeating our analyses 
with data sets derived from patients in clinical environments that differ from the HOPS, 
including at the national level (eg, the Medical Monitoring Project), to further evaluate the 
performance characteristics of this engagement metric.
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TABLE 1
Characteristics of Patients With At Least 1 HIV Laboratory Test Not Associated With a Medical Encounter 
Versus Patients With All Tests Associated With Medical Encounters, HOPS Data, 2010–2011 (N = 2909 
Participants)*
Any Laboratory Test Not Associated With
a Medical Encounter N = 761 (26.2%)
All Laboratory Tests Associated With
Medical Encounters N = 2148 (73.3%)
n (%) n (%) P
Age (yrs) as of index date 0.11
 18–34 110 (14.5) 261 (12.2)
 35–44 204 (26.8) 547 (25.5)
 45–54 313 (41.1) 887 (41.3)
 55+ 134 (17.6) 453 (21.1)
Gender 0.64
 Female 161 (21.2) 437 (20.3)
 Male 600 (78.8) 1711 (79.7)
Race† 0.04
 Hispanic 85 (11.2) 262 (12.2)
 Non-Hispanic black 207 (27.2) 681 (31.7)
 Non-Hispanic white 437 (57.4) 1104 (51.4)
 Other/Unknown 32 (4.2) 101 (4.7)
Education 0.08
 Less than high school 74 (9.7) 253 (11.8)
 High school graduate/GED 106 (13.9) 290 (13.5)
 Some college or other training 180 (23.7) 415 (19.3)
 College graduate 247 (32.5) 712 (33.2)
 Other/Unknown 154 (20.2) 478 (22.3)
Insurance status‡ <0.01
 Private 445 (58.5) 1191 (55.5)
 Public 205 (26.9) 727 (33.9)
 Other 111 (14.6) 230 (10.7)
Disease stage as index date 0.19
 HIV only (non-AIDS) 335 (44.0) 887 (41.3)
 AIDS 426 (56.0) 1261 (58.7)
HIV risk group 0.32
 HRH 192 (25.2) 539 (25.1)
 IDU 50 (6.6) 157 (7.3)
 MSM 478 (62.8) 1299 (60.5)
 Other/unknown§ 41 (5.4) 153 (7.1)
ART status as of index date 0.02
 Naive 68 (8.9) 138 (6.4)
 Experienced 681 (89.5) 1955 (91.0)
 Unknown 12 (1.6) 55 (2.6)
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Any Laboratory Test Not Associated With
a Medical Encounter N = 761 (26.2%)
All Laboratory Tests Associated With
Medical Encounters N = 2148 (73.3%)
n (%) n (%) P
Facility type <0.01
 Private practice 329 (43.2) 664 (30.9)
 University clinic 432 (56.8) 1484 (69.1)
AIDS, acquired immunodeficiency syndrome; GED, general education development examination; HRH, high-risk heterosexual contact; IDU, 
intravenous drug use; MSM, men who have sex with men.
*
This table looks at patient-level characteristics.
†
Patients of Hispanic ethnicity, regardless of white or black race, were categorized as Hispanic.
‡
Private insurance included preferred provider organizations, health maintenance organizations, and point of service. Medicare, Medicaid, and 
Ryan White/AIDS Drug Assistance Program were considered public funding.
§
Includes patients with no identified risk, transfusion/transplant recipients, patients with hemophilia, patients infected through perinatal 
transmission, exposed health care professionals, and patients infected through cultural/ritual practices.
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TABLE 2
Cross-Tabulation of Health Resources and Services Administration Encounter-Based Definition of 
Engagement in Care by Laboratory-Based Definition, HOPS Data, 2010–2011 (N = 2909 Participants)*




 of engaged in care
 Yes 2201 (75.7%) 48 (1.7%) 2249 (77.3%)
 No 366 (12.6%) 294 (10.1%) 660 (22.7%)
2567 (88.2%) 342 (11.8%) 2909
*
Sensitivity = 2201/2567 × 100 = 85.7; specificity = 294/342 × 100 = 86.0; positive predictive value = 2201/2249 × 100 = 97.9; negative predictive 
value = 294/660 × 100 = 44.5.
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TABLE 3
Characteristics of Patients With Engagement Correctly Classified Versus Incorrectly Classified by the Proxy 
Laboratory Measure, HOPS Data, 2010–2011 (N = 2909 Participants)*
Misclassified
Correctly Classified False Negatives False Positives
N = 2495 (85.5%) N = 366 (12.6%) N = 48 (1.7%)
Characteristic N % N % P † N % P †
Age at index date 0.006 0.56
 18–34 316 12.7 48 13.1 7 14.6
 35–44 624 25.0 118 32.2 9 18.8
 45–54 1031 41.3 145 39.6 24 50.0
 ≥55 524 21.0 55 15.0 8 16.7
Sex at birth 0.003 0.46
 Female 494 19.8 97 26.5 7 14.6
 Male 2001 80.2 269 73.5 41 85.4
Race/ethnicity‡ <0.001 0.018
 Hispanic 297 11.9 50 13.7 0 0.0
 Non-Hispanic black 726 29.1 144 39.3 18 37.5
 Non-Hispanic white 1358 54.4 154 42.1 29 60.4
 Other/Unknown 114 4.6 18 4.9 1 2.1
HIV risk category <0.001 0.079
 MSM 1545 61.9 196 53.6 36 75.0
 HRH 595 23.9 125 34.2 11 22.9
 IDU 183 7.3 24 6.6 0 0.0
 Other/unknown§ 172 6.9 21 5.7 1 2.1
HRH, high-risk heterosexual contact; IDU, intravenous drug use; MSM, men who have sex with men.
*
This table looks at patient-level characteristics. Please see the text for explanation of false-negative and false-positive classifications.
†
P values are derived from χ2 tests comparing false negatives to patients correctly classified and from Fisher exact tests comparing false positives 
to patients correctly classified.
‡
Patients of Hispanic ethnicity, regardless of white or black race, were categorized as Hispanic.
§
Includes patients with no identified risk, transfusion/transplant recipients, patients with hemophilia, patients infected through perinatal 
transmission, exposed health care professionals, and patients infected through cultural/ritual practices.
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TABLE 4
Odds of HIV Laboratory Testing Event Not Being Associated With a Medical Encounter, HOPS Data, 2010–
2011 (N = 10,321 Laboratory Events)*
Bivariate Analysis Multivariate Analysis
Characteristic OR (95% CI) P OR (95% CI) P
Age at index date (10-yr increments) 0.9 (0.9 to 1.00) 0.047 0.9 (0.9 to 1.01) 0.07
Gender
 Female 1.0 (0.8 to 1.2) 0.80
 Male Referent
Race/ethnicity†
 Hispanic 0.9 (0.7 to 1.1) 0.15 1.0 (0.8 to 1.2) 0.83
 Non-Hispanic black 0.7 (0.6 to 0.9) <0.01 0.9 (0.7 to 1.03) 0.10
 Non-Hispanic white Referent Referent
HIV transmission risk
 HRH 0.9 (0.8 to 1.1) 0.32
 IDU 0.8 (0.7 to 1.1) 0.16
 MSM Referent
Education
 Less than high school 0.8 (0.7 to 1.02) 0.07
 High school or equivalent 1.0 (0.8 to 1.3) 0.91
 Some college 1.1 (0.9 to 1.3) 0.38
 College graduate Referent
Facility
 Private practice 1.8 (1.5 to 2.1) <0.01 1.6 (1.4 to 1.9) <0.01
 University clinic Referent Referent
Insurance‡
 Public 0.7 (0.6 to 0.8) <0.01 0.9 (0.8 to 1.04) 0.15
 Private Referent Referent
Disease stage
 HIV only (non-AIDS) 1.1 (0.97 to 1.3) 0.11
 AIDS Referent
ART exposure
 Naive 1.5 (1.2 to 1.9) <0.01 1.5 (1.2 to 1.9) <0.01
 Experienced Referent Referent
Plasma HIV RNA viral load suppressed§
 No 1.1 (0.9 to 1.3) 0.23
 Yes Referent
Viral load suppressed at last laboratory test§
 No 1.1 (0.9 to 1.2) 0.45
 Yes Referent
Switched ART since last medical encounter
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Bivariate Analysis Multivariate Analysis
Characteristic OR (95% CI) P OR (95% CI) P
 No 1.0 (0.9 to 1.2) 0.89
 Yes Referent
CD4 cell count (cells/mm3)
 <200 0.9 (0.7 to 1.2) 0.43
 200–349 1.1 (0.9 to 1.3) 0.54
 350–499 0.9 (0.8 to 1.1) 0.19
 500+ Referent
CI, confidence interval; HfY, human immunodeficiency virus; HRH, high-risk heterosexual contact; IV, intravenous; MSM, men having sex with 
men; OR, odds ratio.
*
This table is at the laboratory events level; some patients are reflected in multiple events.
†
Patients of Hispanic ethnicity, regardless of white or black race, were categorized as Hispanic.
‡
Private insurance included preferred provider organizations, health maintenance organizations, and point of service. Medicare, Medicaid, Ryan 
White/AIDS Drug Assistance Program, etc., were considered public funding.
§
Viral loads were considered suppressed if <400 RNA copies per milliliter.
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